Muscular Dystrophy Trial, Recruiting NCT06925269 Sponsor: Red Nucleus Enterprise Solutions, LLC Condition: Muscular Dystrophy
Back to Muscular Dystrophy

Muscular Dystrophy Trial, Recruiting

NCT06925269
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For patients (Group A):

  • You must have been taking the medication Givinostat for at least 2 years
  • You must be at least 10 years old, with a parent or legal guardian who has agreed to your participation
  • You must currently be taking Givinostat
  • You must be willing and able to take part in an interview that may be recorded by video and/or audio

For caregivers of a patient in Group A:

  • You must be a parent or legal guardian of someone with Duchenne Muscular Dystrophy (DMD) who has been taking Givinostat for at least 2 years
  • You must be willing and able to take part in an interview that may be recorded by video and/or audio

For caregivers in Group B:

  • You must care for someone with DMD who is unable to raise their hands above their head
  • You must live in the United States or Canada
  • You must be able to read, speak, and understand English
  • You must be willing and able to take part in an interview that may be recorded by video and/or audio
  • You must have a reliable internet connection

Who may not be able to join:

  • No specific exclusion criteria were listed for this trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Mindy Leffler, M.Ed., Red Nucleus Solutions

Phone: 904-541-9326

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Red Nucleus Enterprise Solutions, LLC
Registry
ClinicalTrials.gov
Start date
31 March 2025
Est. completion
1 December 2025

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Qualitative Interview

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov